

# **Liquid Biopsy Market Size, Share, and Analysis, By Product (Services, Kits & Reagents, and Platforms & Instruments), By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles, and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cytometry, Digital PCR), By Application (Diagnosis and Screening, Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034**

<https://marketpublishers.com/r/LF3039417EC2EN.html>

Date: January 2025

Pages: 603

Price: US\$ 5,250.00 (Single User License)

ID: LF3039417EC2EN

## **Abstracts**

Liquid Biopsy Market Size, Share, and Analysis, By Product (Services, Kits & Reagents, and Platforms & Instruments), By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles, and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cytometry, Digital PCR), By Application (Diagnosis and Screening, Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

## **PRODUCT OVERVIEW**

Liquid Biopsy Market is projected to exhibit a Compound Annual Growth Rate (CAGR)

of 15.3% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 5.1 billion and is projected to reach USD 24.7 billion by the completion of 2034.

Liquid biopsy is a non-invasive diagnostic test that identifies disease indicators in bodily fluids, such as blood. It is particularly useful in detecting genetic and molecular alterations, especially in cancer. Unlike traditional biopsies that require surgical procedures to obtain tissue samples, liquid biopsies involve a simple blood test or fluid sample collection, making the process less invasive and more accessible. Liquid biopsy is utilized for early cancer detection, monitoring treatment response, tracking disease progression, and identifying minimal residual disease and relapse. Techniques like Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Digital Droplet PCR are employed to detect and analyze genetic mutations, chromosomal abnormalities, and disease biomarkers. Beyond cancer, liquid biopsy is also used to test for genetic defects in unborn babies, monitor organ transplant rejection, and is becoming applicable in heart, infection-related, and immune system disorders.

## MARKET HIGHLIGHTS

Liquid Biopsy Market is expected to reach USD 24.7 billion during the forecast period, driven by the increasing demand for non-invasive diagnostics. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, thus increasing its use for various diagnostic purposes. As global cancer cases continue to rise, there is a growing need for tools that can detect and monitor the disease in its early stages, leading to a higher demand for liquid biopsies. Additionally, advancements in technologies such as PCR, NGS, and Digital Droplet PCR enhance the precision and sensitivity of liquid biopsies, further fueling market growth. New technological advancements are also making liquid biopsies more accurate and affordable, making them more accessible to healthcare providers and patients.

### Liquid Biopsy Market Segments:

By Product

Services

Kits & Reagents

Platforms & Instruments

By Circulating Biomarker

Circulating Tumor DNA

Circulating Tumor Cell

Extracellular Vesicles

Others

By Technology

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Cytometry

Digital PCR

By Application

Diagnosis and Screening

Treatment Monitoring

Prognosis and Recurrence Monitoring

Treatment Selection

## MARKET DYNAMICS

Growth Drivers

Increasing Cancer Incidence is Critical to Boost the Adoption of Liquid Biopsy

Advancements in Technology Will Aid the Market

*Liquid Biopsy Market Size, Share, and Analysis, By Product (Services, Kits & Reagents, and Platforms & Instrum...*

Restraint

High Costs Can Limit the Growth of the Liquid Biopsy Market

Key Players

Guardant Health, Inc.

QIAGEN N.V.

Natera, Inc.

Singular Genomics Systems, Inc.

Exosome Diagnostics, Inc.

Illumina, Inc.

Asuragen, Inc.

MDxHealth SA

Thermo Fisher Scientific Inc.

Epigenomics AG

Sysmex Corporation

Circulating Cell-Free Genome Atlas (CCGA)

Foundation Medicine, Inc.

Biocept, Inc.

Roche Holding AG

Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis,

Recent Development, Regional Presence, SWOT Analysis)

Global Laboratory Temperature Control Units Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada

Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe

Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC

Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

#### Reasons to Purchase this Report

Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market of various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

3-month post-sales analyst support.

## Contents

### **1.EXECUTIVE SUMMARY**

- 1.1. Regional Market Share
- 1.2.Business Trends
- 1.3. Liquid Biopsy Market: COVID-19 Outbreak
- 1.4. Regional Trends
- 1.5. Segmentation Snapshot

### **2. RESEARCH METHODOLOGY**

- 2.1.Research Objective
- 2.2. Research Approach
- 2.3. Data Sourcing and Methodology
- 2.4.Primary Research
- 2.5.Secondary Research
  - 2.5.1.Paid Sources
  - 2.5.2. Public Sources
- 2.6. Market Size Estimation and Data Triangulation

### **3. MARKET CHARACTERISTICS**

- 3.1.Market Definition
- 3.2.Liquid Biopsy Market: COVID-19 Impact
- 3.3. Key Segmentations
- 3.4.Key Developments
- 3.5.Allied Industry Data

### **4.LIQUID BIOPSY MARKET – INDUSTRY INSIGHTS**

- 4.1. Industry Segmentation
- 4.2.COVID-19 overview of world economy
- 4.3.Industry Ecosystem Channel Analysis
- 4.4.Innovation & Sustainability

### **5. MACROECONOMIC INDICATORS**

### **6. RECENT DEVELOPMENTS**

## **7. MARKET DYNAMICS**

- 7.1.Introduction
- 7.2. Growth Drivers
- 7.3. Market Opportunities
- 7.4.Market Restraints
- 7.5. Market Trends

## **8.RISK ANALYSIS**

## **9. MARKET ANALYSIS**

- 9.1.Porter's Five Forces
- 9.2. PEST Analysis
  - 9.2.1.Political
  - 9.2.2. Economic
  - 9.2.3. Social
  - 9.2.4. Technological

## **10.LIQUID BIOPSY MARKET**

- 10.1.Overview
- 10.2. Historical Analysis (2018-2022)
  - 10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

## **11. LIQUID BIOPSY MARKET SIZE & FORECAST 2024A-2034F**

- 11.1. Overview
- 11.2.Key Findings
- 11.3.Market Segmentation
  - 11.3.1.By Product
    - 11.3.1.1. Services
      - 11.3.1.1.1.By Value (USD Million) 2024A-2034F
      - 11.3.1.1.2. Market Share (%) 2024A-2034F
      - 11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
    - 11.3.1.2.Kits & Reagents
      - 11.3.1.2.1. By Value (USD Million) 2024A-2034F
      - 11.3.1.2.2.Market Share (%) 2024A-2034F



- 11.3.1.2.3.Y-o-Y Growth (%) 2024A-2034F
- 11.3.1.3.Platforms & Instruments
  - 11.3.1.3.1. By Value (USD Million) 2024A-2034F
  - 11.3.1.3.2.Market Share (%) 2024A-2034F
  - 11.3.1.3.3.Y-o-Y Growth (%) 2024A-2034F
- 11.3.2. By Circulating Biomarker
  - 11.3.2.1.Circulating Tumor DNA
    - 11.3.2.1.1. By Value (USD Million) 2024A-2034F
    - 11.3.2.1.2.Market Share (%) 2024A-2034F
    - 11.3.2.1.3.Y-o-Y Growth (%) 2024A-2034F
  - 11.3.2.2. Circulating Tumor Cell
    - 11.3.2.2.1.By Value (USD Million) 2024A-2034F
    - 11.3.2.2.2. Market Share (%) 2024A-2034F
    - 11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
  - 11.3.2.3. Extracellular Vesicles
    - 11.3.2.3.1.By Value (USD Million) 2024A-2034F
    - 11.3.2.3.2. Market Share (%) 2024A-2034F
    - 11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
  - 11.3.2.4. Others
    - 11.3.2.4.1.By Value (USD Million) 2024A-2034F
    - 11.3.2.4.2. Market Share (%) 2024A-2034F
    - 11.3.2.4.3. Y-o-Y Growth (%) 2024A-2034F
- 11.3.3.By Technology
  - 11.3.3.1.Polymerase Chain Reaction (PCR)
    - 11.3.3.1.1. By Value (USD Million) 2024A-2034F
    - 11.3.3.1.2.Market Share (%) 2024A-2034F
    - 11.3.3.1.3.Y-o-Y Growth (%) 2024A-2034F
  - 11.3.3.2. Next-Generation Sequencing (NGS)
    - 11.3.3.2.1.By Value (USD Million) 2024A-2034F
    - 11.3.3.2.2. Market Share (%) 2024A-2034F
    - 11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
  - 11.3.3.3. Cytometry
    - 11.3.3.3.1.By Value (USD Million) 2024A-2034F
    - 11.3.3.3.2. Market Share (%) 2024A-2034F
    - 11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
  - 11.3.3.4. Digital PCR
    - 11.3.3.4.1.By Value (USD Million) 2024A-2034F
    - 11.3.3.4.2. Market Share (%) 2024A-2034F
    - 11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F

#### 11.3.4.By Application

##### 11.3.4.1.Diagnosis and Screening

11.3.4.1.1. By Value (USD Million) 2024A-2034F

11.3.4.1.2.Market Share (%) 2024A-2034F

11.3.4.1.3.Y-o-Y Growth (%) 2024A-2034F

##### 11.3.4.2. Treatment Monitoring

11.3.4.2.1.By Value (USD Million) 2024A-2034F

11.3.4.2.2. Market Share (%) 2024A-2034F

11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F

##### 11.3.4.3. Prognosis and Recurrence Monitoring

11.3.4.3.1.By Value (USD Million) 2024A-2034F

11.3.4.3.2. Market Share (%) 2024A-2034F

11.3.4.3.3. Y-o-Y Growth (%) 2024A-2034F

##### 11.3.4.4.Treatment Selection

11.3.4.4.1.By Value (USD Million) 2024A-2034F

11.3.4.4.2. Market Share (%) 2024A-2034F

11.3.4.4.3. Y-o-Y Growth (%) 2024A-2034F

## **12.NORTH AMERICA LIQUID BIOPSY MARKET SIZE & FORECAST 2024A-2034F**

### 12.1.Overview

### 12.2. Key Findings

### 12.3. Market Segmentation

#### 12.3.1.By Product

#### 12.3.2. By Circulating Biomarker

#### 12.3.3. By Technology

#### 12.3.4. By Application

### 12.4. Country

#### 12.4.1. United States

#### 12.4.2. Canada

## **13.EUROPE LIQUID BIOPSY MARKET SIZE & FORECAST 2024A-2034F**

### 13.1.Overview

### 13.2. Key Findings

### 13.3. Market Segmentation

#### 13.3.1.By Product

#### 13.3.2. By Circulating Biomarker

#### 13.3.3. By Technology

- 13.3.4. By Application
- 13.4. Country
  - 13.4.1. Germany
  - 13.4.2. United Kingdom
  - 13.4.3. France
  - 13.4.4. Italy
  - 13.4.5. Spain
  - 13.4.6. Russia
  - 13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

## **14.ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE & FORECAST 2024A-2034F**

- 14.1. Overview
- 14.2. Key Findings
- 14.3. Market Segmentation
  - 14.3.1. By Product
  - 14.3.2. By Circulating Biomarker
  - 14.3.3. By Technology
  - 14.3.4. By Application
- 14.4. Country
  - 14.4.1. India
  - 14.4.2. China
  - 14.4.3. South Korea
  - 14.4.4. Japan
  - 14.4.5. Rest of APAC

## **15.MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET SIZE & FORECAST 2024A-2034F**

- 15.1. Overview
- 15.2. Key Findings
- 15.3. Market Segmentation
  - 15.3.1. By Product
  - 15.3.2. By Circulating Biomarker
  - 15.3.3. By Technology
  - 15.3.4. By Application
- 15.4. Country
  - 15.4.1. Israel
  - 15.4.2. GCC

- 15.4.3. North Africa
- 15.4.4. South Africa
- 15.4.5. Rest of Middle East and Africa

## **16. LATIN AMERICA LIQUID BIOPSY MARKET SIZE & FORECAST 2024A-2034F**

- 16.1. Overview
- 16.2. Key Findings
- 16.3. Market Segmentation
  - 16.3.1. By Product
  - 16.3.2. By Circulating Biomarker
  - 16.3.3. By Technology
  - 16.3.4. By Application
- 16.4. Country
  - 16.4.1. Mexico
  - 16.4.2. Brazil
  - 16.4.3. Rest of Latin America

## **17. COMPETITIVE LANDSCAPE**

- 17.1. Company market share, 2023
- 17.2. Key player overview
- 17.3. Key stakeholders

## **18. COMPANY PROFILES**

- 18.1. Guardant Health, Inc.
  - 18.1.1. Company Overview
  - 18.1.2. Financial Overview
  - 18.1.3. Key Product; Analysis
  - 18.1.4. Company Assessment
    - 18.1.4.1. Product Portfolio
    - 18.1.4.2. Key Clients
    - 18.1.4.3. Market Share
    - 18.1.4.4. Recent News & Development (Last 3 Yrs.)
- 18.2. QIAGEN N.V.
- 18.3. Natera, Inc.
- 18.4. Singular Genomics Systems, Inc.
- 18.5. Exosome Diagnostics, Inc.

- 18.6. Illumina, Inc.
- 18.7. Asuragen, Inc.
- 18.8. MDxHealth SA
- 18.9. Thermo Fisher Scientific Inc
- 18.10. Epigenomics AG
- 18.11. Sysmex Corporation
- 18.12. Circulating Cell-Free Genome Atlas (CCGA)
- 18.13. Foundation Medicine, Inc
- 18.14. Biocept, Inc.
- 18.15. Roche Holding AG
- 18.16. Other Prominent Players

## **19. APPENDIX**

## **20. CONSULTANT RECOMMENDATION**

## I would like to order

Product name: Liquid Biopsy Market Size, Share, and Analysis, By Product (Services, Kits & Reagents, and Platforms & Instruments), By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles, and Others), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cytometry, Digital PCR), By Application (Diagnosis and Screening, Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

Product link: <https://marketpublishers.com/r/LF3039417EC2EN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LF3039417EC2EN.html>